Disease Landscape and Forecast 인사이트
종합적인 시장 정보와 실행 가능한 인사이트를 통해 장기적인 질병 전략을 최적화하세요.
Renal Anemia in Chronic Kidney Disease Non-Dialysis | Chart Trends | China | 2014
Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define…
Patient Access to High-Cost Therapies for CML in LATAM: How Do Payers and Physicians Shape This Crowded and Changing Market? | Physician & Payer Forum | Brazil and Mexico | 2014
The treatment armamentarium for chronic myelogenous leukemia (CML) in Brazil and Mexico includes all three currently marketed tyrosine kinase inhibitors (TKIs): Glivec (imatinib,Novartis) for newly…
The Impact of EU5 Payer Policy on Prescribing in Non-Hodgkin’s Lymphoma and Multiple Myeloma | Physician & Payer Forum | EU5 | 2014
In Europe, multiple myeloma (MM) treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and Celgene’s Thalidomide (…
Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome (Novel Oral Anticoagulants – Evolving Treatments ) | Physician & Payer Forum | China | 2014
Warfarin has been the mainstay of anticoagulation therapy for the past several decades, but difficulties associated with its use and the clinical management of patients have prompted the…
Marketing to U.S. Digital Physicians: Engaging Physicians Across Screens and Platforms
Changes in U.S. policy have accelerated the implementation and use of electronic health records (EHRs) in the practice, disrupting physician workflow and decision making. In the meanwhile, reliance…
Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | Decision Base | US/EU | 2014
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive)…
